The Effects of FR-167653 on Postoperative Intimal Hyperplasia of the Interposition Vein Graft in Rat: 2nd Report.
10.4326/jjcvs.32.75
- VernacularTitle:ラットｉｎｔｅｒｐｏｓｉｔｉｏｎ ｖｅｉｎ ｇｒａｆｔにおけるＴＮＦ‐α産生阻害剤ＦＲ‐１６７６５３の術後内膜肥厚抑制効果 続報
- Author:
Mitsuhiro Yamamura
;
Hideki Yao
;
Takashi Miyamoto
- Publication Type:Journal Article
- Keywords:
tumor necrosis factor-α (TNF-α);
p38 mitogen-activated protein kinase;
FR-167653
- From:Japanese Journal of Cardiovascular Surgery
2003;32(2):75-78
- CountryJapan
- Language:Japanese
-
Abstract:
Recently we reported that the inhibitor of p38 mitogen-activated protein kinase, FR-167653 (Fujisawa Pharm. Co., Ltd., Osaka) may suppress postoperative intimal hyperplasia. In this study we evaluated the best dosage and phase for administration of FR-167653, in order to clarify its mechanism in the postoperative treatment of intimal hyperplasia. Twenty-one Lewis male rats (484±5g) were studied. The epigastric vein graft was interposed into the common femoral artery. The rats were divided into four groups according to the dosage and phase of administration of FR-167653: group I (n=5) with 2.0μg/g of FR-167653 immediately before bypass, group T (n=5) with 2.0μg/g immediately before bypass and 2 weeks after bypass, group D (n=5) with 4.0μg/g immediately before bypass, and the control group (n=6) with the same dose of saline. The intimal areas of vein grafts were measured at 4 weeks postoperatively. The mean intimal areas in group I, T and D were significantly decreased compared with the control group, especially in group D (0.05±0.02mm2 vs. 0.43±0.05mm2, p<0.001). These results suggest that FR-167653 can suppress the postoperative intimal hyperplasia that occurs with interposition of vein grafts in rats.
